



April 30, 2026

Company name: Mitsubishi Chemical Group Corporation  
Representative: Manabu Chikumoto  
Representative Corporate Executive Officer,  
President and Chief Executive Officer  
Listed on the Prime Market of TSE (stock  
code: 4188  
Contact: [Press inquiries]  
Corporate Communications Office  
Tel: (+81) (0)3-6748-7140  
[IR inquiries]  
Investor Relations Office  
Tel: (+81) (0)3-6748-7120

### Notice Regarding Changes in Specified Subsidiaries

Mitsubishi Chemical Group Corporation (hereinafter “MCG”) hereby announces that there has been a change in our specified subsidiary as detailed below.

#### 1. Reason for the Change

Nippon Sanso Holdings Corporation (TSE Prime: 4091; Head office: Shinagawa-ku, Tokyo; Representative Director, President CEO: Toshihiko Hamada; hereinafter “NSHD”), a consolidated subsidiary of MCG, reached an agreement to acquire Esteve Teijin Healthcare, S.L., which was under Corporación Químico-Farmacéutica Esteve and Teijin Holdings Europe B.V. and operates home healthcare services business in Spain. The acquisition was made through Oximesa S.L.U., the Spanish subsidiary of its European subsidiary, Nippon Sanso Euro-Holding S.L.U. (formerly Nippon Gases Euro-Holding S.L.U.).

On March 3, 2026, NSHD completed the procedures to acquire the shares of the target company based on this agreement and subsequently renamed the acquired company to “Nippon Sanso Homecare España, S.L.U.”. After acquiring the shares of the company and making it a subsidiary, NSHD conducted a review of the company’s past capital transactions and it has been determined that Nippon Sanso Homecare España, S.L.U., which became a consolidated subsidiary, has become MCG’s specified subsidiary because its capital corresponds to an amount equivalent to 10% or more of MCG’s capital.

#### 2. Overview of the Subsidiary Subject to Change

(1)	Name	Nippon Sanso Homecare España, S.L.U.
(2)	Location	Passeig del Ferrocarril, 369, P. I. Camí Ral, 08860 Castelldefels, Barcelona, Spain
(3)	Name and title of representative	Director Justin Corcho(Mr.)
(4)	Line of business	Home healthcare services business
(5)	Capital	EUR 35.7 million
(6)	Establishment	February 2009
(7)	Major shareholder(s) and ownership	Oximesa S.L.U. 100%

percentage			
(8) Relationship between the listed company and the relevant company	Capital Relationship	The company is a 100% owned subsidiary of Oximesa S.L.U., which is NSHD's European subsidiary.	
	Personnel Relationship	None	
	Business Relationship	None	
(9) Operating results and financial status of the relevant company for the last three years			
Fiscal Year	Fiscal Year ended December 2022	Fiscal Year ended December 2023	Fiscal Year ended June December 2024
Net Assets	12 million EUR	14 million EUR	36 million EUR
Total Assets	47 million EUR	61 million EUR	59 million EUR
Revenue	33 million EUR	37 million EUR	40 million EUR
Operating Profit	4 million EUR	3 million EUR	3 million EUR
Net Profit	3 million EUR	2 million EUR	2 million EUR

## 5. Date of Transfer

March 3, 2026

## 6. Future Outlook

The impact of this matter has been incorporated into the full-year consolidated earnings forecast for the fiscal year ending March 2026, announced on February 5, 2026.